Enlivex Therapeutics Statistics

Total Valuation

Enlivex Therapeutics has a market cap or net worth of ILS 121.69 million. The enterprise value is 26.65 million.

Market Cap	121.69M
Enterprise Value	26.65M

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Shares Outstanding	n/a
Shares Change (YoY)	+2.08%
Shares Change (QoQ)	+4.37%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	15.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.32
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.41

Financial Position

The company has a current ratio of 10.06, with a Debt / Equity ratio of 1.18.

Current Ratio	10.06
Quick Ratio	9.57
Debt / Equity	1.18
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -61.17% and return on invested capital (ROIC) is -30.05%.

Return on Equity (ROE)	-61.17%
Return on Assets (ROA)	-27.46%
Return on Capital (ROIC)	-30.05%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.61% in the last 52 weeks. The beta is 1.03, so Enlivex Therapeutics's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	-31.61%
50-Day Moving Average	486.48
200-Day Moving Average	791.20
Relative Strength Index (RSI)	66.11
Average Volume (20 Days)	18,417

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.47

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-70.24M
Pretax Income	-83.94M
Net Income	-83.94M
EBITDA	-67.37M
EBIT	-70.24M
Earnings Per Share (EPS)	-4.45

Full Income Statement

Balance Sheet

The company has 97.67 million in cash and 1.27 million in debt, giving a net cash position of 96.41 million.

Cash & Cash Equivalents	97.67M
Total Debt	1.27M
Net Cash	96.41M
Net Cash Per Share	n/a
Equity (Book Value)	107.54M
Book Value Per Share	5.15
Working Capital	96.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -64.09 million and capital expenditures -357,685, giving a free cash flow of -64.45 million.

Operating Cash Flow	-64.09M
Capital Expenditures	-357,685
Free Cash Flow	-64.45M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Enlivex Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.08%
Shareholder Yield	-2.08%
Earnings Yield	-86.20%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a